Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle. Its transdermal gel products comprise Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company also offers OTREXUP, an injection for subcutaneous use indicated for adults with severe active RA, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis, as well as Vibex auto injectors. In addition, it is developing Vibex QS T for testosterone replacement therapy for men who have testosterone deficiency; Vibex QS M with an undisclosed drug for treatment of a CNS indication; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Meda Pharmaceuticals, Inc.; Pfizer Inc; Population Council; and LEO Pharma, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.